Immune cells defective for SUV39H1

Patent metadata

Field	Value
Publication number	US-12371471-B2
Application number	US-202418895296-A
Country	US
Kind code	B2
Filing date	Sep 24, 2024
Priority date	Jun 20, 2017
Publication date	Jul 29, 2025
Grant date	Jul 29, 2025

Abstract

The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically hinds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.

First claim

The invention claimed is:

1. A method of producing a modified T-cell or NK cell in vivo with inhibited SUV39H1 activity comprising administering to a patient (a) an antisense molecule or RNA interfering agent that specifically targets a SUV39H1 gene or SUV39H1 gene product, or (b) a gene editing agent that specifically targets and disrupts the SUV39H1 gene.

2. The method of claim 1 , wherein the T cell is a CD4+ or CD8+ T cell.

3. The method of claim 1 , wherein the patient is administered the antisense molecule or RNA interfering agent, and wherein the antisense molecule is antisense RNA or antisense DNA, or the RNA interfering agent is siRNA, shRNA, miRNA or a ribozyme.

4. The method of claim 1 , wherein the patient is administered the gene editing agent, and wherein the gene editing agent is a zinc finger nuclease (ZFN), a TALE nuclease (TALEN), an RNA-guided endonuclease, a CRISPR-Cas, or a meganuclease.

5. The method of claim 1 further comprising administering to the patient simultaneously or sequentially a vector encoding a genetically engineered antigen receptor that specifically binds to a cancer or tumor antigen or a modified T cell or NK cell expressing a genetically engineered antigen receptor that specifically binds to a cancer or tumor antigen.

6. The method of claim 3 further comprising administering to the patient simultaneously or sequentially a vector encoding a genetically engineered antigen receptor that specifically binds to a cancer or tumor antigen or a modified T cell or NK cell expressing a genetically engineered antigen receptor that specifically binds to a cancer or tumor antigen.

7. The method of claim 4 further comprising administering to the patient simultaneously or sequentially a vector encoding a genetically engineered antigen receptor that specifically binds to a cancer or tumor antigen or a modified T cell or NK cell expressing a genetically engineered antigen receptor that specifically binds to a cancer or tumor antigen.

8. The method of claim 5 wherein the RNA interfering agent or gene editing agent is administered after the vector or modified T cell or NK cell is administered.

9. The method of claim 3 wherein the antisense molecule or RNA interfering agent is administered by in vivo transcription of DNA sequences from a vector encoding the RNA molecule.

10. The method of claim 4 wherein the gene editing agent is administered by an expression vector, optionally a viral vector.

11. An in vitro, in vivo or ex vivo method of reducing SUV39H1 activity of an immune cell during production of an immune cell for cell therapy of a patient, comprising contacting the immune cell with an antisense molecule or RNA interfering agent that specifically targets a SUV39H1 gene or SUV39H1 gene product.

12. The method of claim 11 wherein the antisense molecule is antisense RNA or antisense DNA, or where the RNA interfering agent is siRNA, shRNA, miRNA or a ribozyme.

13. The method of claim 11 wherein the contacting is in vivo.

14. An in vitro, in vivo or ex vivo method of reducing SUV39H1 activity of an immune cell during production of an immune cell for cell therapy of a patient, comprising contacting the immune cell with a gene editing agent that specifically targets and disrupts the SUV39H1 gene.

15. The method of claim 14 , wherein the gene editing agent is a zinc finger nuclease (ZFN), a TALE nuclease (TALEN), an RNA-guided endonuclease, a CRISPR-Cas, or a meganuclease.

16. The method of claim 14 , wherein the contacting is in vivo.

Assignees

• Inst Curie
• Institut National De La Sante Et De La Rech Medical Inserm
• Centre Nat Rech Scient
• Inst Nat Sante Rech Med
• Centre Nat Rech Scient

Inventors

• Amigorena Sebastian
• Piaggio Eliane
• Goudot Christel
• Pace Luigia
• Almouzni Genevieve
• Niborski Leticia

Classifications

• A61K40/42

  Cancer antigens · CPC title

• A61K40/32

  T-cell receptors [TCR] · CPC title

• A61K40/31

  Chimeric antigen receptors [CAR] · CPC title

• A61K40/15

  Natural-killer [NK] cells; Natural-killer T [NKT] cells · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title